Another novel ATM inhibitor KU59403 with enhanced potency and specificity against ATM radiosensitized CRC cell lines independent of TP53 status, providing important preclinical data to support the clinical development of ATM inhibitors in the future [67]. This evidence concerns the gene TP53 and colorectal carcinoma.